Bristol-Myers Squibb and Samsung BioLogics Expand Manufacturing Agreement

News
Article

PTSM: Pharmaceutical Technology Sourcing and Management

PTSM: Pharmaceutical Technology Sourcing and ManagementPTSM: Pharmaceutical Technology Sourcing and Management-05-07-2014
Volume 10
Issue 5

Bristol-Myers Squibb and Samsung BioLogics expand their manufacturing agreement to cover biologic medicines.

Bristol-Myers Squibb and Samsung BioLogics have expanded their existing manufacturing agreement, in which Samsung will manufacture commercial drug substances and drug product for several Bristol-Myers Squibb biologic medicines at Samsung's Incheon, China manufacturing site. Financial terms of the agreement are not disclosed.

Bristol-Myers Squibb and Samsung announced their first manufacturing agreement in July 2013 to collaborate in the production of a single commercial antibody cancer drug substance.

Source: Bristol-Myers Squibb

Recent Videos
DC skyline at night with view of the White House and the Washington Monument | Image Credit: © Jessica - stock.adobe.com
Behind the Headlines, Episode 18
Drug Digest: Patient Preference Drives Solid Dosage Trends
Behind the Headlines, Episode 17
Related Content